Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Advances in™: Application of Proteasome Inhibitor Therapies Across the MM Disease Spectrum

Release Date: December 15, 2021
Expiration Date: December 15, 2022


Activity Overview

In the United States, an estimated 34,920 people will be diagnosed with multiple myeloma (MM) and an estimated 12,410 persons will die of the disease in 2021. Since the approval of the first-in-class proteasome inhibitor (PI) bortezomib in 2003, PIs have been crucial in treatment of MM. The second-generation PIs carfilzomib and ixazomib have also entered the clinic following United States Food and Drug Administration (FDA) approval in 2012 and 2015, respectively. How and when to use PIs, including in frontline, relapsed/refractory, and maintenance therapy settings, are areas of active investigation. There is also an array of different combination strategies available that include PIs, and each is associated with different adverse event profiles which impact tolerability considerations. With so many treatment options available, clinicians are hard-pressed to remain up to date with the plethora clinical trial data, the knowledge of which is imperative to optimal treatment selection and outcomes for patients.

This online educational activity is designed to provide expert interpretation of new and emerging data on the use of PIs for the treatment of MM, with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of risk stratification, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
 

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.



Target Audience

This educational program is directed toward hematologists and medical oncologists interested in the treatment of hematologic malignancies. Other allied healthcare professionals, including nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the impact of disease-related factors, risk stratification and treatment history on therapy decision-making in MM
  • Assess the efficacy and safety profiles of current and emerging PI-based regimens investigated in multiple lines of care for the treatment of MM
  • Place into clinical context the impact of recent trial evidence from investigations that assessed PI-based strategies among patients with MM

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 
 

Faculty

Vaishali Sanchorawala, MD
Sagar Lonial, MD, FACP
Professor and Department Chair
Department of Hematology and Medical Oncology
Emory University
Atlanta, Georgia
 

Disclosures: Grant/Research Support: Takeda Oncology, Janssen, Bristol Myers Squibb, Celgene; Consultant: Takeda Oncology, Amgen, Janssen, Bristol Myers Squibb, Celgene, Novartis, AbbVie; Board With Stock: TG Therapeutics.

 
Omar K. Siddiqi, MD
Meletios A. Dimopoulos, MD
National and Kapodistrian University of Athens
Department of Clinical Therapeutics
School of Medicine
Athens, Greece

 


Disclosures:  Grant/Research Support/Advisory Board: Amgen, Takeda Oncology, Bristol Myers Squibb, Janssen, BeiGene.


PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
 

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By